Clinical Trial

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2020 (before its estimated December 31, 2020 completion). Its status may not reflect the trial's current state.
Summary
This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-07-24; most recent amendment 2024-04-05.
Status change: Recruiting → Completed 2023-01-11
Trial Details
NCT Number NCT04490031
Lead Sponsor Universiti Kebangsaan Malaysia Medical Centre
Conditions Ketamine Adverse Reaction
Enrollment 140 participants
Start Date 2020-03-01
Primary Completion 2020-12-31 (estimated)
Study Completion 2021-04-30 (estimated)
Updated on ClinicalTrials.gov 2020-07-28